Viatris to Buy Pacira for $1.65 Billion in Non-Opioid Pain Push

Viatris said Thursday it will acquire Pacira BioSciences for $36.50 a share in cash, an aggregate equity value of $1.65 billion and a 45 percent premium over Pacira's closing price the day before. The deal hands the generic-drug maker two marketed, patent-protected pain medicines that carry no opioids, and it is expected to close by the end of 2026.

Pacira's portfolio centers on Exparel, an injectable form of the long-used local anesthetic bupivacaine packaged in liposomes to release slowly after surgery, and Zilretta, an extended-release injection of the corticosteroid triamcinolone acetonide for knee osteoarthritis. Pacira reported roughly $746 million in revenue and $177 million in adjusted EBITDA over the twelve months ended June 30, 2026; its two largest products accounted for about $692 million in 2025 sales.

Old molecules, new delivery, and a hard sales problem

Neither drug is a new chemical entity. Exparel and Zilretta are reformulations of generic compounds whose value sits in how they are delivered — a distinction that has made Exparel a fixture in hospital pain protocols and a frequent target in the debate over whether expensive non-opioid options actually displace opioid prescriptions.

That debate has constrained growth. Analysts have noted that Exparel's uptake has been limited by hospital formularies reluctant to add it to standard post-surgical protocols, and Pacira recently won coverage from UnitedHealthcare, one of the largest commercial insurers in the country. Pacira says its portfolio has helped nearly 20 million patients get non-opioid pain management.

"The addition of EXPAREL, for acute postsurgical pain, and ZILRETTA, for osteoarthritis knee pain, are synergistic with our fast-acting meloxicam market opportunity and position us as a leader in non-opioid pain management therapies, an area where patients and healthcare providers continue to seek more treatment options," Viatris chief executive Scott A. Smith said in the announcement.

Why a generics company is buying brands

Viatris built its business on off-patent drugs and now wants a larger share of higher-margin branded medicine. The Pacira purchase follows its pattern of buying on-market commercial assets rather than early-stage research. Viatris already sells the pain medications Celebrex and Relpax, and it is waiting on a Food and Drug Administration decision — due by December 27 — on a fast-acting formulation of meloxicam.

Viatris interim chief financial officer Paul Campbell said the company expects to fund the transaction mostly from excess cash with the remainder from short-term borrowings, and that it expects the acquisition to be immediately accretive to its financial guidance.

The transaction is structured as a tender offer followed by a second-step merger. Pacira's board unanimously recommends that shareholders tender, and the company will become a wholly owned Viatris subsidiary and leave the Nasdaq Global Select Market once the deal closes.

The patent clock is already running

Exparel's exclusivity is not open-ended. Settlements Pacira reached in 2025 with Fresenius Kabi and a subsidiary of Hengrui Pharma allow those companies to begin marketing generics in early 2030, starting at a high single-digit share of total U.S. volume and escalating into the 30 percent range within three years. Manufacturing patents Pacira secured in 2024 pushed its listed protection on Exparel to 2044, according to the FDA's Orange Book, though two other manufacturers are challenging those patents. Patents covering Zilretta run to 2031.

Viatris said it plans to "leverage its intellectual property expertise and proven ability to extend product lifecycles" after generics arrive — the same lifecycle-management playbook it applies elsewhere in the portfolio. Analysts read the deal as steady rather than transformative. Leerink's Daniel Clark wrote that he does not anticipate "a meaningfully different near-term trajectory" for the products but likes that Viatris is executing on capital deployment and adding sources of margin expansion into the 2030s.

Where this lands in the opioid conversation

Non-opioid pain therapies moved into the spotlight in August, when the FDA approved suzetrigine, the first novel non-opioid pain drug in decades. Exparel and Zilretta belong to an older generation of that effort: reformulations of drugs that never contained an opioid, sold on the argument that better acute pain control reduces the number of prescriptions that seed dependence.

That argument matters because most people who develop opioid use disorder start with a prescription written for surgery, injury or chronic pain. Fewer pills leaving the pharmacy is not the same as treating the people already dependent, however — medication for opioid use disorder remains the intervention with the strongest evidence, and the two halves of the supply-side and treatment-side response draw from different budgets and different politics.

Exparel's own commercial record also suggests the limits of substitution: the drug has been available since 2011, and opioid prescribing after surgery has fallen sharply over the same period for reasons that include tightened guidelines, state prescription limits and prescriber behavior — not only new products.